Developing Best-in-Class Antibiotics to Combat the Rise of Bacterial Resistance; Report Available here: www.lifescicapital.com/equity-research/paratek/
NEW YORK, NY / ACCESSWIRE / May 13, 2015 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of Paratek Pharmaceuticals (NasdaqGM: PRTK), a biotechnology company developing novel antibiotics to combat the rise of bacterial resistance. The Company's lead compound, omadacycline, has been shown to have broad spectrum activity against a wide range of clinically-relevant bacteria including key drug-resistant strains.
Paratek is developing omadacycline as a treatment for acute skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), and also intends to pursue an indication for complicated urinary tract infections (cUTI) in the future. Its broad spectrum of activity, combined with a favorable safety and tolerability profile and convenient once-daily dosing, should allow for omadacycline to become a key monotherapy option in treating a wide range of serious community-acquired infections. Paratek has reported positive results in a Phase II trial for ABSSSI and plans to launch two Phase III trials in 2015, one for ABSSSI and one for CABP.
In a 40 page Initiation Report, LifeSci Capital explains the Company's development program, the landscape of existing therapies, and the favorable shift in regulatory and economic environment that now support development in the antibiotic space.
Dr. Isaacson's full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on Paratek Pharmaceuticals as developments occur.
The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.
About LifeSci Capital:
LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients' businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company's website, www.lifescicapital.com.
Analyst Contact:
Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com
SOURCE: LifeSci Capital LLC